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The regulation of the synthesis of a-2-HS glyeoprotein (AHSG) by inflammatory mediators from activated monocytes 
was studied on the human hepatoma cell line HepG2 and compared to that of albumin. Monocyte-conditioned medium, 
recombinant human interleukin-6 (rhlL6) and interleukin-lfl (rhlLlfl) all down-regulated the synthesis of AHSG. This 
decrease was found both at the protein and the mRNA level. The most efficient mediator was the monocyte-conditioned 
medium, when rhlLlfl was found to be less efficient han rhlL6. The combination of rhlL6 and rhlLlfl resulted in an 
additive down-regulation f the AHSG mRNA levels. Similar results were obtained with albumin. These data indicate 
that AHSG is a negative acute-phase protein whose synthesis regulated by cytokines in a manner similar to that of 
albumin. 
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1. INTRODUCTION 
ce-2-HS glycoprotein (AHSG) is a glycoprotein 
with a molecular mass of 50 kDa, which is found 
in normal human plasma at values around 
60 mg/dl. No exact function has yet been deter- 
mined for this protein, although it has been found 
to be concentrated in bone matrix during 
mineralization [1]. In addition, recent data in- 
dicate that it has the ability to regulate the flux of 
calcium in vitro from bone [2]. It has also the 
capacity to act as an opsonin [3] and to promote 
endocytosis [4]. Furthermore, its plasma levels 
decrease significantly during an inflammatory 
response [5]. 
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In response to inflammation, the levels of some 
plasma proteins synthesized by the liver increase 
(positive acute-phase proteins) whereas others 
decrease (negative acute-phase proteins) [6]. The 
levels of each protein return to their basal values 
following the end of the acute-phase of the inflam- 
matory response. The local reaction includes the 
release of inflammatory mediators ecreted by 
human monocytes [7,8]. Hepatocyte-stimulating 
factor (HSF) [9,10], interleukin-1 (ILl) [11] and 
tumor necrosis factor (TNFc~) [12] are considered 
as being the major mediators of the acute-phase 
response. Recently, HSF and interleukin(IL)-6 
(BSF2, IFNB2, 26 kDa protein and interleukin 
HP-1) were found to be functionally and im- 
munologically identical [13,14]. In the rat 
hepatoma cell line Fao, acute-phase proteins are 
regulated ifferently by the mediators IL6, ILI~ 
and TNFce, indicating that the acute-phase 
response is more complex than previously de- 
scribed [15]. 
In the present study, we have analyzed the pro- 
duction of ce-2-HS (AHSG) by human hepatoma 
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(HepG2)  cells in the presence  o f  CM f rom LPS-  
ac t ivated  monocytes  as well  as us ing  the two 
fo l low ing  cytok ines :  rh IL1B and  rh IL6 .  Our  
resu l ts  ind icate  that  AHSG is a negat ive  acute-  
phase  prote in  whose  synthes is  is down- regu la ted  
by  cytok ines .  
2. MATERIALS  AND METHODS 
2.1. Hepatoma cell cultures 
HepG2 cells were grown in RPMI medium containing 10% 
FCS, 50 U/ml penicillin, 50 ,ug/ml streptomycin, 1/~M insulin, 
and were passaged by trypsinisation once a week. When the 
cells reached 80 to 100% confluency, equal volumes of CM 
from stimulated monocytes (see below) and fresh RPMI 
medium plus FCS were added and cells were incubated for 24 
or 48 h. Cells cultivated with fresh medium only were used as 
controls. The culture media were collected after either 24 or 
48 h, and analyzed by rocket immuno-electrophoresis to deter- 
mine the levels of AHSG and albumin produced. HepG2 cells 
were similarly exposed to cytokines (see below) for 48 h at dif- 
ferent concentrations. 
3. RESULTS AND DISCUSSION 
The  human hepatoma (HepG2)  cell l ine was 
used to quant i ta te  AHSG and a lbumin  secret ion  
and  mRNA levels, be fore  and  a f ter  t reatment  wi th  
CM o f  monocytes  and  pur i f ied  cytok ines ,  in o rder  
to  eva luate  the in f luence  o f  these med ia tors  on  the 
synthes is  o f  these two prote ins .  Es t imat ion  o f  the 
!. 
ACHT 
2.2. Preparation of  the conditioned medium 
Human peripheral blood monocytes were separated by 
buoyant density centrifugation, purified by adherence and 
stimulated with lipopolysaccharide (LPS) (10,ug/ml) (E. coli 
055:B5, Sigma) for 24 h. The supernatant was dialyzed against 
phosphate buffered saline and sterilized by filtration through a
0.22 ,am membrane (Millipore). 
ALB 
2.3. Recombinant cytokines 
Purified human rlLlfl (1000 U/ml) was purchased from Gen- 
zyme (TEBU SA, France). Purified rBSF2 (lot 703) (1 × 
l0 s U/19.3/~g per ml) was generously provided by T. Hirano 
and T. Kishimoto (Institute of Molecular and Cellular Biology, 
Osaka, Japan) [16]. 
2.4. cDNA probes 
Human albumin cDNA (pHSA59B3) was kindly provided by 
Dr M. Frain (Lab. Enzymologie, CNRS, Gif-sur-Yvette, 
France) and o~-2-HS cDNA was obtained as described [17]. 
2.5. Analysis of  secreted proteins 
Concentrations of the proteins were determined by electro- 
immunoassay [18] using monospecific antisera to human 
plasma proteins. The results were expressed as'ag/ml of protein 
for 24 or 48 h. 
2.6. Northern analysis of  mRNA levels 
Cells (5 × 106 per flask) were lysed in ITG. Total cellular 
RNA was extracted, separated by electrophoresis in 1.2% 
agarose gels containing formaldehyde and transferred to nylon 
membrane (Amersham) [19]. The RNA was fixed by UV il- 
lumination. The blots were then prehybridized and hybridized 
overnight with 32p-labelled cDNA probes. The cDNAs were 
radiolabelled by oligonucleotide priming [20]. Autoradiography 
of Northern blots was analyzed by densitometric s anning. 
AHSG 
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Fig.1. Quantification of plasma proteins in the medium of 
HepG2 cells by rocket immuno-electrophoresis: effect of the 
conditioned medium from LPS-activated monocytes (CM) on 
the secretion of cr-l-antichymotrypsin (ACHT), albumin (ALB) 
and c~-2-HS (AHSG). Cells were cultured for 48 h in presence 
of normal culture medium (1,2) and with CM (v/v) (3,4). Wells 
were loaded with 50,ul of the cell culture media. 
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Table 1 
Levels of proteins secreted by HepG2 cells treated with conditioned media from LPS-activated 
monocytes (CM) 
Control CM CM/control 
Time (h): 24 48 24 48 24 48 
ACHT 8.00 _ 4.49 13.05 _+ 5.70 14.46 _+ 5.90 22.30 + 6.56 1.81 1.72 
(n = 5) (n = 6) (n = 5) (n = 6) 
Albumin 4.96 + 2.50 4.21 _+ 0.95 2.54 _+ 1.16 2.33 + 0.26 0.51 0.55 
(n=5) (n=6) (n=5) (n=6) 
AHSG 4.06 _+ 2.15 6.23 _+ 3.78 2.80 + 1.58 4.69 +_ 3.56 0.68 0.75 
(n = 5) (n = 6) (n = 6) (n = 6) 
Protein values were expressed as microgram protein secreted in 24 h or 48 h/ml, and were measured 
by rocket immuno-electrophoresis u ng purified protein standards for calibration 
secretion of AHSG, albumin and c~-l-antichymo- 
trypsin (ACHT) was made by rocket immunoelec- 
trophoresis (fig.l). ACHT was used as a positive 
control to characterize the CM activities ince the 
synthesis of ACHT in HepG2 cells is greatly 
enhanced by CM of monocytes [21]. As shown in 
fig.1 and table 1, the addition of CM induced a 
1.81-fold increase in ACHT secretion, after 48 h 
stimulation, whereas that of albumin decreased by 
about fifty percent, and that of AHSG by about 
thirty percent. Further experiments were perform- 
ed using rh lL l~ (30 U/ml)  and rhlL6 (50 U/ml).  
As shown in table 2, IL l  and IL6 increased the syn- 
thesis of ACHT,  but IL6 was a more potent in- 
ducer than IL l .  In contrast, the secretion of 
albumin was decreased both by ILl  and IL6, 
although the most important decrease was observ- 
ed when using CM. Similarly, a moderate decrease 
in the amount of AHSG secretion was observed 
following exposure to recombinant cytokines for 
48 h. 
The amount of specific mRNAs for albumin and 
AHSG was measured by hybridization of cDNA 
probes to total cellular RNA extracted after 48 h 
exposure of HepG2 to cytokines. Fig.2 shows the 
results of the Northern analysis of total cellular 
cr-2-HS RNA. Densitometric scanning of these 
samples indicated that AHSG mRNA at 48 h 
dramatically decreased in treated cells versus con- 
trols, showing a 25% decrease for IL l ,  a 50% 
decrease for IL6, a 75O7o decrease when these two 
cytokines were associated, and a decrease over 
90°70 for the conditioned medium. An important 
decrease of 75O7o in albumin mRNA was observed 
with CM, whereas that obtained with IL6 was 70% 
and was 50O/o with ILl  (not shown). 
Table 2 
Amounts of ACHT, albumin and AHSG secreted by HepG2 cells in response to rhILl,  rhlL6 
and conditioned medium (CM) of monocytes over a 48 h period (ug/ml) 
Treatment ACHT Albumin AHSG 
Level Fold increase Level Fold increase Level Fold increase 
Control 21.0 4.20 16.4 
rhlLlfl (30 U/ml) 30.0 1.43 3.40 0.80 13.0 0.79 
rhlL6 (50 U/ml) 42.0 2.00 3.20 0.76 12.6 0.77 
rhlLl~' + rhlL6 44.0 2.09 3.08 0.73 11.6 0.70 
CM 41.6 1.98 2.30 0.54 11.6 0.70 
Values represent he mean of triplicate cultures and were measured by rocket immuno- 
electrophoresis 
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Fig.2. Northern analysis with human ~-2-HS (AHSG) cDNA 
probe of total cellular RNA (30/zg) from HepG2 cells treated 
over a period of 48 h with different recombinant cytokines and 
conditioned medium. (1) Control; (2) rhlL1 (30 U/ml); (3) 
rhlL6 (50 U/ml); (4) rhlL1 (30 U/ml) + rhlL6 (50 U/ml); (5) 
conditioned medium from LPS-activated human monocytes. 
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cultures using a combinat ion of rhlL6 and rh lL l~.  
In our experiments, rhlL6 appears to be the major  
inducer of the decrease of AHSG synthesis in 
vitro. We have shown previously that the plasma 
concentrat ion of AHSG is decreased uring the 
course of an acute in f lammat ion [5], but it was not 
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